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Abstract
Gentamicin is the preferred antimicrobial agent used in implant coating for the prevention
of implant-related infections (IRI). However, the present heavy local and systemic adminis-
tration of gentamicin can lead to increased resistance, which has made its future use
uncertain, together with related preventive technologies. Fosfomycin is an alternative anti-
microbial agent that lacks the cross-resistance presented by other classes of antibiotics.
We evaluated the efficacy of prophylaxis of 10% fosfomycin-containing poly(D,L-lactide)
(PDL) coated K-wires in a rat IRI model and compared it with uncoated (Control 1), PDL-
coated (Control 2), and 10% gentamicin-containing PDL-coated groups with a single layer
of coating. Stainless steel K-wires were implanted and methicillin-resistant Staphylococcus
aureus (ATCC 43300) suspensions (103 CFU/10 μl) were injected into a cavity in the left tib-
iae. Thereafter, K-wires were removed and cultured in tryptic soy broth and then 5% sheep
blood agar mediums. Sliced sections were removed from the tibiae, stained with hematoxy-
lin-eosin, and semi-quantitatively evaluated with X-rays. The addition of fosfomycin into
PDL did not affect the X-ray and histopathological evaluation scores; however, the addition
of gentamicin lowered them. The addition of gentamicin showed a protective effect after the
28th day of X-ray evaluations. PDL-only coating provided no protection, while adding fosfo-
mycin to PDL offered a 20% level protection and adding gentamicin offered 80%. Further-
more, there were 103 CFU level growths in the gentamicin-added group, while the other
groups had 105. Thus, the addition of fosfomycin to PDL does not affect the efficacy of pro-
phylaxis, but the addition of gentamicin does. We therefore do not advise the use of fosfo-
mycin as a single antimicrobial agent in coating for IRI prophylaxis.
PLOS ONE | DOI:10.1371/journal.pone.0165544 November 2, 2016 1 / 13
a11111
OPENACCESS
Citation: Gulcu A, Akman A, Demirkan AF,
Yorukoglu AC, Kaleli I, Bir F (2016) Fosfomycin
Addition to Poly(D,L-Lactide) Coating Does Not
Affect Prophylaxis Efficacy in Rat Implant-Related
Infection Model, But That of Gentamicin Does.
PLoS ONE 11(11): e0165544. doi:10.1371/journal.
pone.0165544
Editor: Andres R. Floto, Cambridge University,
UNITED KINGDOM
Received: February 17, 2016
Accepted: October 13, 2016
Published: November 2, 2016
Copyright: © 2016 Gulcu et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The author(s) received no specific
funding for this work.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
Implant-related infections (IRI) are most commonly seen as a serious complication if there is
foreignmaterial [1]. It is very difficult to treat due to the formation of biofilms, which decreases
their susceptibility to antibiotics [2–8]. Thus, prevention may be the best form of treatment.
Gentamicin-added poly(D,L-lactide) (PDL) coating has been extensively studied in vitro [9–
11] and in vivo [11–14] for the prevention of IRI. Preliminary reports for a coated tibial intra-
medullary nail show favorable characteristics and effectiveness [14,15]. The present heavy local
and systemic administration of gentamicin can lead to increased resistance, which has made its
future use uncertain, together with related preventive technologies. [16]. By using it in prophy-
laxis, the efficacy of the antibiotic may be lost if it is required in a further infection. Fosfomycin
may be an alternative to gentamicin as it lacks the cross-resistance that other classes of antibiot-
ics present because it acts on synthetic steps unaffected by other agents [17]. It is a broad-spec-
trum antibiotic and is effective against methicillin-resistant Staphylococcus aureus (MRSA)
[18]. Additionally, it has superior osseophilic behavior in contrast with other antibiotic agents,
which may be explained by the similarity in its structure to hydroxyapatite [19,20]. Therefore,
it may be beneficial for the treatment of osseous infections. Furthermore, using fosfomycin in
prophylaxis allows the use of aminoglycosides to treat further infections.
This study evaluated the efficacy of fosfomycin added to a PDL coating in a rat IRI model,
and compared it to a gentamicin-added PDL coating, PDL-only coating, and bare implant.
Materials and Methods
The study was approved by the Experimental Animal Research Ethics Committee of Pamuk-
kale University, Denizli, Turkey (Reg. No.: 60758568-020/58916, Reg. Date: 17/04/2014). The
study was performed in the Experimental Research Unit in Pamukkale University. The rats
were supplied with unlimited tap water (ad libitum) and given standard rodent feed. Animals
were kept in sufficiently large cages at a constant temperature of 22°C with a 12/12 h light/
dark cycle. All applicable international, national, and/or institutional guidelines for the care
and use of animals were followed. All procedures performed in studies involving animals were
in accordance with the ethical standards of the institution or practice at which the studies were
conducted.
The IRI rat model was conducted according to a previously reported protocol [12], with
somemodifications. The pathogen used was MRSA (ATCC 43300). We evaluated the strain
using an Automated Microbiology System (BD Phoenix Automated Microbiology System,
BectonDickinson, NJ, USA), which was found to be resistant to penicillin, oxacillin, clindamy-
cin, and erythromycin, but sensitive to vancomycin, teicoplanin, linezolid, daptomycin, nitro-
furantoin, and gentamicin. The strain was found to be susceptible to fosfomycin using the disc
diffusionmethod [21] (i.e., 48 mm zone of diameter), which is in concordance with previous
reports using the same method [22,23]. (S1 Fig)
PDL (Boehringer Ingelheim, Ingelheim, Germany) was chosen as the biodegradable coating
polymer and drug carrier. PDL was dissolved in 1.5 ml of volatile solvent (Chloroform; Sigma-
Aldrich, St. Louis, USA) at room temperature. Lyophilized gentamicin sulfate (80 mg/2 ml,
generic) or fosfomycin sodium (Ventranal; Sigma-Aldrich, St. Louis, USA) was suspended in
the solution and added according to each groups need, yielding a concentration of 10% genta-
micin or fosfomycin at the base weight to weight (w/w) of the polymer. The solution was sterile
filtered. Sterilized stainless steel (S-steel) K-wires 0.8 mm in diameter were dipped into the
solution and dried under sterile laminar airflow conditions. The coating process was done only
once (Fig 1). K-wires were kept in sterile conditions until implantation.
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Forty female, 3-month-oldWistar albino rats with averaging weight of 250 g were used in
the study. The rats were randomly assigned to one of four groups:
Group 1: Uncoated group (Control 1),
Group 2: PDL-only coated group (Control 2),
Group 3: Gentamicin-added PDL coated group, and
Group 4: Fosfomycin-added PDL coated group.
Surgery was performed under general anesthesia by a weight-adopted intraperitoneal injec-
tion of 2% xylazine (12 mg/kg) and ketamine hydrochloride (80 mg/kg). The left hind leg was
shaved, and disinfectedwith 10% povidone-iodine solution. The animals were placed on sterile
drapes, the bodies were covered, except the left hind leg, with sterile sheets, and the left hind
foot was draped separately. Skin and fascia at the proximal tibial metaphysis were incised (5
mm in length).With a hand-driven burr, a 1 mm diameter K-wire was drilled through the cor-
tical and cancellous bone to access the medullary cavity of the proximal metaphysis. The med-
ullary cavity was bluntly reamed with K-wire in order to reach the narrowing distal part of the
tibial cavity. After removal, 10 μl of bacterial suspension containing 103 CFU/10 μl MRSA was
injectedwith a 50 μl micro syringe for contamination of the medullary cavity. A suitable K-
wire was inserted into intramedullary cavity (Fig 2a). The excess parts of the K-wires were cut
Fig 1. Electron microscopy image at 325x magnification showing the poly(D,L-lactide) (PDL) coating.
doi:10.1371/journal.pone.0165544.g001
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off at the site of entry. Soft tissue was irrigated, and skin and fascia were interruptedly sutured
with a single knot technique.
Animals were followed up for 42 days and then sacrificed.All procedures were carried out
with intraperitoneal anesthesia. On the day of surgery and regularly throughout the observa-
tion period, the body weight and body temperature of rats were measured. The clinical condi-
tions of the animals were checked and X-rays of the left tibia in two planes were performed.On
days 1, 3, 7, 14, 21, 28, 35, and 42, their rectal body temperature was measured using a digital
thermometer and recorded as CentigradeCelsius (°C), and body weight was determined using
a precision scale and recorded as grams. Animals were inspected for clinical signs of infection
(appearance of wound and soft tissue at entry site of implant, joint effusion, loss of mobility,
general condition). On days 1, 14, and 42, blood samples (1 to 2 ml) were taken from the right
atriums and evaluated for the hemoglobin (Hb) level (g/dl) and white blood cell (WBC) count
(1000/μl).
X-rays of the anterior-posterior and lateral views were performed on days 1, 7, 14, 28, 35,
and 42, with a distance from focus to film of 110 cm. A digital X- ray unit is used to assess the
development and progression of bone infection. The following three regions of interest (ROI)
were determined and separately evaluated (Fig 3): (R1) proximal epi-/metaphysis, (R2) diaphy-
sis, and (R3) distal epi-/metaphysis. The following radiographic appearances were assessed
according to a modified score by An and Friedman [24]: (1) Periosteal reaction, (2) Osteolysis,
Fig 2. Implantation. (a) Implantation of K-wire into rat tibias and (b) a view of the entrance site of K-wire after being sacrificed.
doi:10.1371/journal.pone.0165544.g002
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(3) Soft tissue swelling, (4) Deformity, (5) General impression, (6) Spontaneous fracture, and
(7) Sequestrum formation. Parameters 1 to 5 ranged from 0 (absent), 1 (mild), 2 (moderate) to
3 (severe) and were evaluated for every ROI. Parameters 6 and 7 were judged as 0 (absent) or 1
(present). For assessment of parameters 6 and 7, radiographs were not subdivided into ROI.
All radiographs were scored in comparison to the 1st day radiographs. The maximum score
achievable was 47.
On day 42, under intraperitoneal anesthesia, the chest cavity was opened. Three milliliters
of bloodwas drawn from the right atrium and put into an aerobic culture medium (BD BAC-
TEC FX; BectonDickinson,Maryland, USA). Then, a lethal dose of potassium chloride was
applied by intracardiac injection. The tibiae of the left hind legs were dissected under sterile
conditions using separate instruments for preparation of the skin and the tissue underneath
(Fig 2b). A swapping culture was taken from the K-wire entrance with a transport swap. The
entire soft tissue was removed. The K-wires were placed in 2.5 ml of sterile TSB mediums after
sonofication and incubated at 37°C for 48 h. The suspensions were subsequently diluted (1:1,
1:10, and 1:100) and 10 μl of samples were streaked on 5% sheep blood agar (SBA) plates and
incubated at 37°C for 48 h. After that, the CFUs on SBA plates were counted visually and bacte-
rial growth in the TSB was judged (cloudy: positive growth; clear: no growth). Bacteria isolated
from cultures were evaluated by a catalase test, plasma coagulase test, gram staining, and auto-
mated microbiology system for the identification of contamination and evaluation of resis-
tance. There were no contaminating S. aureus species in this study as very strict isolating rules
were applied (Fig 4).
Longitudinal sections 5 μm thick were cut by a microtome at the sagittal plane. Slices were
stained with hematoxylin-eosin (H&E) (Sigma-Aldrich, St. Louis, USA). Slices of the same
bone plane were evaluated for the following parameters, according to a modified score of Petty
et al. [25]: (1) Abscess formation, (2) Sequestrum formation, (3) Cortical enlargement, and (4)
Cortical destruction. Parameters were scored semi-quantitatively as: 0 (absent), 1 (mild), 2
(moderate) and 3 (present). All parameters were assessed for each ROI. The maximum score
achievable was 12 (Fig 5).
Fig 3. X-ray evaluation. (a) Illustration showing the region of interests in a lateral X-ray (R1: Proximal epi-/metaphysis, R2: Diaphysis and R3: Distal
epi-/metaphysis), and (b) different levels of X-ray finding in four different subjects. (Note: Numbers denote the subject’s group).
doi:10.1371/journal.pone.0165544.g003
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SPSS v22 (IBM, New York, USA) was used for statistical evaluation. A non-parametric
Kruskal-Wallis Test was used for independent group comparisons, whereas a Friedman test
was used for dependent groups. Data were analyzed within 95% confidence intervals and a P
value less than 0.05 was considered statistically significant.
Results
Osteomyelitis was established in all subjects of control groups. Mean body weights, body tem-
peratures, Hb, andWBC counts did not significantly change at the follow-up time in all groups.
From the X-ray evaluations, Group 4 shows significantly lower scores than Group 1 on the
14th day and 21st day (p< 0.001 and p = 0.013 respectively), but not after or before these days.
Group 4 did not show significantly lower scores than Group 2 or higher scores than Group 3 in
all evaluations. In contrast, Group 3 showed significantly lower scores than Group 1 on the 7th
day (p = 0.003), and Group 1 and 2 on the 14th day (p< 0.001 and p = 0.005, respectively) and
21st day (p< 0.001 and p = 0.004 respectively), but not after. Group 3 showed significantly
lower scores than Groups 1, 2, and 4 on the 28th day (p< 0.001, p< 0.001, and p = 0.004,
respectively), 35th day (p< 0.001, p = 0.001, and p = 0.003, respectively), and 42nd day
(p< 0.001, p = 0.001, and p = 0.001, respectively). Thus, the addition of fosfomycin to PDL did
not alter X-ray scores, but the addition of gentamicin did lower the scores. The resultant effects
of the addition of gentamicin started to show from the 28th day (Fig 6).
From the histopathological evaluation, Group 3 showed significantly lower scores compared
to Group 1 or Group 2 but not Group 4 (p = 0.004, p = 0.049, and p = 0.240, respectively). In
contrast, Group 4 showed lower scores than Group 1 or 2, but these values did not reach a
statistically significant level. Thus, the addition of fosfomycin to PDL showed no difference
according to the histopathological scoring, but the addition of gentamicin reduced the scores
compared to the controls (Table 1).
Fig 4. Bacterial growth on 5% sheep blood agar after implant rolling in demonstration samples. (a) No bacterial growth and (b) bacterial
growth.
doi:10.1371/journal.pone.0165544.g004
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There was no bacterial growth on the K-wire entrance swapping cultures or blood cultures.
Over 105 CFU level bacterial growths were observed in all samples from Groups 1 and 2 in
SBA cultures. The same level of bacterial growth was observed in 8/10 samples in Group 4. In
contrast, there were 103 CFU level growths in 2/10 samples from Group 3. The TSB mediums
were cloudy in all samples from Groups 1 and 2, 8/10 in Group 4, and 2/10 in Group 3, how-
ever the rest of the mediums were clear. Thus, the bacterial growths in TSB mediums are in
concordance with the culture swapping results. PDL-only coating provided no protection.
From Table 1, the microbiological evaluation shows that the addition of fosfomycin to PDL
gave a 20% level protection whilst the addition of gentamicin gave 80%.
Discussion
S. aureus is the most common cause of osteomyelitis, whether implant-related or not [26].
Direct application of potential antimicrobial agents to the tissue-implant interface may provide
better infection prophylaxis. Coating the implant surface with antimicrobial peptides can
Fig 5. Histopathological evaluation. Abscess (black arrow) and sequestrum (red arrow) formation (a and b) compared with normal histology (c and
d) in hematoxylin-eosin (H&E) staining, with x10 and x20 magnification, respectively.
doi:10.1371/journal.pone.0165544.g005
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reduce the adhesion of bacteria and biofilm formation, and therefore have a potential protec-
tive role in IRI [27]. As an alternative drug for gentamicin, fosfomycin shows antimicrobial
activity against biofilms, particularly in combination with fluoroquinolones or aminoglycosides
against gram-negative bacteria [28–31]. Fosfomycin can penetrate multilayer biofilms and
studies suggest that the penetration into the cells occurs in the low growth rate phase [30]. Fos-
fomycin can also disintegrate biofilms to enhance the permeability of other antibiotics, as seen
with studies on gram-negative bacteria [32]. However, there is controversy over whether this
occurs in MRSA [23].
A thin layer of PDL can be used as carrier of many kinds of bioactive agents due to its biode-
gradability [33–39]. It is highly biocompatible to bone tissue and does not interfere with bone
Fig 6. Changes in the mean radiological scores for groups by time.
doi:10.1371/journal.pone.0165544.g006
Table 1. Histopathological and microbiological evaluation results.
Medium Group 1 Group 2 Group 3 Group 4
Histopathological score¶ H&E 10.2 ± 1.6 (9–12) 9 ± 1.6 (7–11) 2.4 ± 1.1 (1–4) 8.2 ± 1.3 (7–10)
Microbiological results# SBA 10* (100%) 10* (100%) 2** (20%) 8* (80%)
TSB 10 (100%) 10 (100%) 2 (20%) 8 (80%)
¶Values are given in form of mean ± standard deviation (minimum—maximum).
#Values are given in the form of infected medium number in the group (ratio %).
*Over 105 CFU level growth,
**103 CFU level growth.
doi:10.1371/journal.pone.0165544.t001
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healing processes [40,41]. Studies on the release kinetics of PDL found that bioactive agents are
released rapidly with an initial burst and followed by a slow release of up to 14 to 16 weeks
[9,11,39,42]. However, the release kinetics changes if there is a thick layer of polymer. An in
vitro study found that the entirety of gentamicin is released if one layer of PDL coating is
applied, whereas only one-third of the drug remained if the coating was four layers thick [9].
A research group from Germany extensively studied the protection potential of gentamicin-
added PDL coating against MRSA. In their first study, they compared 10% w/w gentamicin-
containing PDL coated titanium K-wires with uncoated and PDL-only coatings using a rat
model of IRI (MRSA with 103 CFU IS). The addition of gentamicin achieved a 30% level pro-
tection [12]. In their second study, using same model but with lower inoculum size (IS) (102),
they compared the same coated implant with systemically applied gentamicin (4 mg/kg, single
shot prior to surgery) and combination of systemic and local application. They found that for
prevention, local application is better than systemic, and the protection ratios were 90%, 15%,
and 80%, respectively [13]. In their third study, they compared the same groups in their first
study with a placebo, and compared systemic application to local application. They found that
systemic application provides 15% protection, whereas local application provides 85% [14].
The systemic usage in their experiments was very short lived (i.e. single shot) compared to the
local usage, due to the drug release profile of the polymer, and thus should be interpreted
accordingly. Our results (80% protection ratio with gentamicin) are in accordance with previ-
ous studies (including our reference model study), despite the higher IS of our study (103).
Additionally, we used an S-steel implant, to which S. aureus adheres to better [43,44].
Several studies on the treatment of IRI in animal models induced by MRSA inoculation
have compared various regiments of systemic antibiotic application. A study using a rat osteo-
myelitis model found that vancomycin provides no protection, however, fosfomycin therapy is
100% protective (108 CFU IS) [34]. In a tissue-cagemodel using rats (105 CFU IS), the combi-
nation of daptomycin-rifampicin showed the highest protection ratio (94%) compared to dap-
tomycin-rifampicin and fosfomycin-rifampicin (82% and 79%, respectively) [45]. In another
tissue-cagemodel using guinea pigs (106 CFU IS), the most effective therapy was found to be a
combination of fosfomycin-rifampicin (83%) followed by daptomycin-rifampicin (67%) [23].
Concerning local application, one study examined the effects of fosfomycin-rifampicin in
combination in an IRI model using ink-jet coating technology [46]. Coated or uncoated S-steel
K-wires were inserted into the rabbit tibiae, which were contaminated with 105 or 106 CFU IS
of methicillin-sensitive or -resistant S. aureus. Rifampicin-fosfomycin coating showed excellent
antibacterial activity (100%) compared to the controls (0%). However, fosfomycin monother-
apy was not included in their study. Furthermore, their work did not include a carrier agent,
which alters the release kinetics.
Our results indicate that adding fosfomycin to the PDL coating makes has a minimal impact
on the protection ratio, as we found a 20% ratio with fosfomycin but 80% with gentamicin.
Furthermore, there were 103 CFU level growths in two samples of the gentamicin-added
group, whereas the other groups had 105 CFU level growths. Our results also question the anti-
biofilm effect of fosfomycin on MRSA.
One limitation of our study is the limited number of samples, with only 10 subjects per
group. As such, the statistical power of our study was limited. The comparison of different ISs
(102 and 106 CFU) would improve our understanding of the effect of adding fosfomycin to
PDL and therefore improve any potential advice given to clinicians, based on the severity of the
infection.We could have been usedmore fosfomycin dosage, but it should be remembered that
higher antibiotic concentrations may impair the integrity of the polymer and the use of multi-
ple layer coatings may lead to some unreleased drug. Additionally, no pharmacokinetic/phar-
macodynamics evaluations were performed in this study nor any additional procedures to
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detect small colony variants or resistance development. Therefore, we consider this a pilot
study. Lastly, the differences in responses to infections in the different groups should be
considered carefully, as the body weights of subjects in the different groups were not paired.
In summary, we found that the addition of fosfomycin to PDL makes no difference to pro-
phylaxis efficacy, however gentamicin does. Thus, fosfomycin should not be used as a single
antimicrobial agent in PDL coating for IRI prophylaxis. Further research is required to eluci-
date the ineffectiveness of fosfomycin.
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